The solution isnt to avoid caloric restrictionits to actively counteract metabolic slowdown by increasing energy expenditure through targeted interventions
Final Thoughts GLP-1 patches may seem like a convenient shortcut, but the reality is that there is currently no over-the-counter patch that contains an FDA-approved GLP-1 receptor agonist medication
drug-related AEs were reported by 58.6% of those receiving survodutide, with half of these participants reporting drug-related GI disorders
In principle, that means Retatrutide attacks the energy-balance equation from both sides at once less in, more out which is the pharmacological rationale for why its trial weight reductions exceeded what the single and dual agonists had achieved
At BMS, the focus is on looking beyond a single marker integrating nutrition, metabolism, inflammation balance, and overall recovery status to support the body more comprehensively